20 hrs ago
Following Smart Money: Baker Brothers LLC Investments In 2013 And Beyond
Perhaps the most important buying indicator for a developmental pharma is who is buying the stock.
Progenics Pharmaceuticals: 6 Driving Factors For Near-Term Stock Price Appreciation
Progenics Pharmaceuticals is an interesting biotech speculative play moving forward into the New Year.
Progenics Pharmaceuticals Announces Completion of Enrollment of...
Progenics Pharmaceuticals, Inc., an oncology company focused on developing innovative approaches to targeting and treating prostate cancer, today announced that it has completed enrollment of chemotherapy experienced patients in a Phase II trial to assess the anti-tumor activity and tolerability of its antibody drug conjugate, PSMA ADC in patients ... (more)
Progenics: Investors Should Remain Cautious Heading Into The Relistor Panel
In March 2014, the FDA will be convening an Advisory Committee for input on the sNDA application for Salix and Progenics' injectable opioid induced constipation agent Relistor, which will include pain, GI, safety, and cardiovascular experts.
Stocks to Keep Your Eyes on- Progenics Pharmaceuticals, Inc....
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
New Report Available: Progenics Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report
The report covers the company's structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360deg view of the company.
Progenics Pharmaceuticals, Inc. Relaunching Registrational Trial Of...
Progenics Pharmaceuticals, Inc. today announced that it is resuming a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, Azedraa , in patients suffering from pheochromocytomas.
Progenics to relaunch Azedra study
Molecular Insight Pharmaceuticals suspended the trial back in 2010 in order to find more funding.